返回 
加入收藏
通心络胶囊对冠心病患者PCI术后血清亲环素A和基质金属蛋白酶9的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 通心络胶囊对冠心病患者PCI术后血清亲环素A和基质金属蛋白酶9的影响 |
| TITLE： | |
| 摘要： | 目的：探讨通心络胶囊对冠心病患者经皮冠状动脉介入治疗（PCI）术后血清亲环素A（CyPA）和基质金属蛋白酶9（MMP-9）的影响。方法： 拟行PCI术的115例冠心病患者随机分为对照组（59例）和观察组（56例）。对照组患者给予常规治疗；观察组患者在对照组治疗的基础上于术后第1天开始口服通心络胶囊0.78 g，每日3次，连用6个月。观察两组患者手术前后的CyPA、MMP-9水平及不良反应发生情况。结果：术前，两组患者血清CyPA、MMP-9水平比较，差异均无统计学意义（P＞0.05）。两组患者术后1 d、1个月及对照组患者术后6个月CyPA水平均显著高于同组术前，但观察组术后1、6个月显著低于对照组，且随时间延长逐渐降低，差异均有统计学意义（P＜0.05）；术后1 d两组间及观察组术后6个月CyPA水平与术前比较，差异均无统计学意义（P＞0.05）。两组患者术后1 d、1个月MMP-9水平均显著高于同组术前，但观察组显著低于对照组，且随时间延长逐渐降低，差异均有统计学意义（P＜0.05）；两组患者术后6个月MMP-9水平与术前比较，差异均无统计学意义（P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义 （P＞0.05 ）。结论：在常规治疗的基础上，通心络胶囊可显著降低冠心病患者PCI术后的CyPA、MMP-9水平，且未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of Tongxinluo capsules on the levels of serum cyclophilin A （CyPA） and matrix metalloproteinase-9 （MMP-9） in patients with coronary heart disease （CHD） after percutaneous coronary intervention （PCI）. METHODS： A total of 115 CHD patients undergoing PCI were randomly divided into control group （59 cases） and observation group （56 cases）. Control group was given conventional treatment. Observation group was additionally given Tongxinluo capsules 0.78 g， 3 times a day， for consecutive 6 months， on the basis of control group. The levels of CyPA and MMP-9 as well as the occurrence of ADR were observed in 2 groups before and after treatment. RESULTS： Before treatment， there was no statistical significance in serum level of CyPA and MMP-9 between 2 groups （P＞0.05）. The levels of CyPA in 2 groups 1 d and 1 month after surgery as well as the level of CyPA in control group 6 months after surgery were all significantly higher than before surgery， but the observation group was significantly lower than the control group 1 and 6 months， this index was decreased gradually as time， with statistical significance （P＜0.05）. There was no statistical significance in the levels of CyPA between 2 groups 1 d after surgery or in observation group between 6 months after surgery and before surgery （P＞0.05）. The levels of MMP-9 in 2 groups 1 d and 1 month after surgery were significantly higher than before surgery， and the observation group was significantly lower than the control group， this index was decreased gradually as time， with statistical significance （P＜0.05）. There was no statistical significance in the levels of MMP-9 of 2 groups between 6 months after surgery and before surgery（P＞0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， Tongxinluo capsules can significantly reduce the levels of CyPA and MMP-9 in CHD patients after PCI. |
| 期刊： | 2017年第28卷第24期 |
| 作者： | 陈国友， 钱玉凤，方存明 |
| AUTHORS： | CHEN Guoyou，QIAN Yufeng，FANG Cunming |
| 关键字： | 冠心病；经皮冠状动脉介入治疗；通心络胶囊；血清亲环素A；基质金属蛋白酶9 |
| KEYWORDS： | Coronary heart disease； Percutaneous coronary intervention； Tongxinluo capsule； Serum cyclophilin A； Matrix metalloproteinase-9 |
| 阅读数： | 257 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
